US Edition
Published • loading... • Updated
Trump to Sign Executive Order on Psychedelic Drug Used Abroad to Treat PTSD
The order would open federal funding for studies on PTSD and traumatic brain injuries while leaving ibogaine classified as a Schedule I drug.
- President Donald Trump is expected to sign an executive order this week encouraging federal research into ibogaine, a psychedelic substance used abroad to treat post-traumatic stress disorder, sources told CBS News.
- Because ibogaine is illegal in the United States, Americans have been traveling to unregulated clinics in Mexico and the Caribbean to seek treatment, operating without U.S. regulatory oversight.
- A 2023 review of 24 studies involving 705 people found that while ibogaine reduced withdrawal symptoms, toxicity to the heart and risk of death were "worrying," with at least 27 fatalities reported.
- Federal officials seek to determine whether the drug is "snake oil" or a legitimate treatment, while Texas Gov. Greg Abbott has already approved $50 million for state-level research into the compound.
- Despite the research push, the administration does not plan to reclassify ibogaine as a Schedule I substance, though news of the order prompted Enveric Biosciences stock to surge around 45% and Psyence Biomedical to reach $6.95.
Insights by Ground AI
13 Articles
13 Articles
Trump expected to sign executive order urging more research into psychedelic ibogaine
President Donald Trump is expected to sign an executive order in the coming days that will encourage more research into the psychedelic ibogaine, according to a person familiar with the order.
·Atlanta, United States
Read Full Article
Marijuana MomentReposted by 
newsbudz.com
newsbudz.comTrump Plans To Sign Executive Order On The Psychedelic Ibogaine As Soon As This Week, Report Says
President Donald Trump is reportedly planning to issue an executive order as soon as this week signaling the administration’s willingness to explore the therapeutic benefits and safety of the psychedelic substance ibogaine. CBS News reported on Thursday that while the administration doesn’t plan to reschedule the psychedelic out of Schedule I of the Controlled Substances Act (CSA) at this time, the move is “meant to open the door to federal fund…
Coverage Details
Total News Sources13
Leaning Left2Leaning Right2Center8Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 17%
C 67%
R 16%
Factuality
To view factuality data please Upgrade to Premium
